Volume Growth Masks Margin Squeeze; Guidance Cut on EO and Freight

Rossari's Q2 headline reads as a victory—revenue hit ₹698 Cr, EBITDA grew 21% YoY, exports accelerated at 34% YoY. But beneath that headline sits a margin trap. Core B2B EBITDA margin contracted 70 basis points year-on-year despite 19% revenue growth and 21% EBITDA dollar growth. That compression is not a rounding error. It signals that pricing power has evaporated as freight costs tripled in some cases and customers are pushing back on absorbing the full impact. When volume can grow 19% but profit growth crawls to 5.5%, something fundamental in the unit economics has shifted.

Three claims broke. On the prior call, management said FY27 revenue growth would be 'unchanged' at ~15%; they now guide 12–14% (mid-teens). The 19% Q2 number does not extrapolate—EO supply delays and logistics headwinds are expected to slow H2 sharply. The margin target fell from 15% (post-B2C exit) to 12%+/–, a 300 basis point miss in confidence. And the EO supply relief that was promised by December 2026? Now expected Q2/Q3 FY28—pushed out four quarters. The new ethoxylation facility sits at 30% utilization. No confirmation yet on incremental Reliance allocation.

That is the earnings call in a sentence. Rossari shipped 34% more (in volume terms) but sent 70 basis points of margin to the ocean. Customers across HPPC, Textile, and AHN segments are not absorbing the full cost increase. Management flagged raw material inflation (phenol, ethylene oxide) and geopolitical disruptions (Middle East turmoil, Bab el-Mandeb chokepoint) as persistent drivers. The margin improvement narrative—hinges on three things: product mix (pharma, aroma, higher-margin), customer price acceptance (uncertain), and tail rationalization (immaterial contribution so far). ROCE has already fallen to low-teens from 20–25%, a signal that new capex (Saudi greenfield, ethoxylation facility, Unitop integration) is not yet accretive.

Management's tone on the call was cautious verging on defensive. When pressed on why margin compression persisted despite 19% growth, the answer was familiar: freight is temporary, it will pass through gradually, and margin uplift will come from pharma and aroma ramp (regulatory approvals pending 6 months to 2 years). When asked about Saudi Arabia greenfield capex details, the response was 'we don't have specifics yet; come back in 8–12 months.' When analysts asked whether Reliance's EO allocation was confirmed, the answer was no—'we are hoping' Q2/Q3 next year brings relief. That is not confidence. It is caution masquerading as prudence.

The stock is down 73.5% from its all-time high of ₹1,619. It trades at ₹429, below its 20-day SMA (₹430.76), 50-day (₹457.65), and 200-day (₹494.69). The RSI is 46.1—neutral bordering on weak. Volume is normal. The 52-week range of ₹375–₹690.30 shows the stock is 14.4% off its low but still 38% off its 52-week high. The drawdown is severe and persistent.

Institution flows tell the story. FII ownership has slipped to 2.02% (down 16 basis points QoQ) after exiting steadily from a peak of 3.98% four quarters ago. DII has also retreated to 14.64% (down 356 basis points QoQ from 18.20% in Q4 FY26). Promoters remain locked at 68.14%. But there is a tell: Bhupesh Kumar Lodha (an insider-linked entity linked to promoter interests) made a bulk buy of 2,98,000 shares at ₹491.50—a price above the current market. That confidence from the inside, when the outside is exiting, warrants attention. It suggests the inside sees value, or at least believes the worst is priced in.